B-link pharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 8,212,731 | 15,058,935 | 17,842,368 | 18,415,269 | 20,150,492 | 18,778,940 | 16,143,118 | 19,434,812 |
| Profit before tax | 277,980 | 403,965 | 867,911 | 683,060 | 617,400 | 632,115 | 318,505 | 242,472 |
| Net profit | 238,068 | 341,058 | 710,135 | 601,883 | 545,088 | 539,129 | 261,626 | 176,296 |
| Equity | 713,177 | 995,411 | 1,767,899 | 2,369,782 | 2,783,881 | 3,170,069 | 3,363,030 | 3,433,315 |
| Liabilities | 639,364 | 1,000,408 | 1,092,893 | 1,021,000 | 1,331,353 | 911,445 | 800,957 | 1,121,516 |
| Non-current assets | 128,127 | 169,356 | 276,940 | 650,705 | 782,672 | 735,384 | 814,807 | 852,570 |
| Current assets | 1,201,649 | 1,869,215 | 2,615,640 | 2,745,032 | 3,315,097 | 3,346,409 | 3,365,410 | 3,837,431 |
| Total assets | 1,329,776 | 2,038,571 | 2,892,580 | 3,395,737 | 4,097,769 | 4,081,793 | 4,180,217 | 4,690,001 |
|
Taxes paid
|
||||||||
| Social insurance contributions | - | - | - | - | - | 157,379 | 194,771 | 195,414 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -16.7% | +83.4% | +18.5% | +3.2% | +9.4% | -6.8% | -14.0% | +20.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 17.9% | 16.7% | 24.6% | 17.7% | 13.3% | 13.2% | 6.3% | 3.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 33.4% | 34.3% | 40.2% | 25.4% | 19.6% | 17.0% | 7.8% | 5.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.9% | 2.3% | 4.0% | 3.3% | 2.7% | 2.9% | 1.6% | 0.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.4% | 2.7% | 4.9% | 3.7% | 3.1% | 3.4% | 2.0% | 1.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.9 | 1.0 | 0.6 | 0.4 | 0.5 | 0.3 | 0.2 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 615,956 | 1,196,740 | 1,169,991 | 1,188,082 | 1,350,868 | 1,287,702 | 983,335 | 1,160,287 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
B-link pharma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-01-16 | 2026-01-29 | 13.79 |
B-link pharma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-14 | 2026-04-14 | 5993.46 |
| 2025-12-18 | 2025-12-18 | 16794.21 |
| 2025-12-17 | 2025-12-17 | 14696.44 |
| 2024-12-17 | 2024-12-17 | 12144.18 |
| 2024-10-16 | 2024-10-16 | 4440.83 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
B-link pharma, UAB (code 302954419) is a Private Limited Liability Company active in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €19.43M and net profit of €176.3K, resulting in a profit margin of 0.9%. Revenue increased by 20.4% year on year in 2025 and was 3.5% higher than two years earlier, but profitability weakened over the period. Net profit declined from €539.1K in 2023 to €261.6K in 2024 and €176.3K in 2025, while the margin narrowed from 2.9% to 1.6% and then to 0.9%. At year-end 2025, total assets stood at €4.69M, equity at €3.43M and liabilities at €1.12M. The company reported an equity ratio of 73.2%, debt-to-equity of 0.33, return on equity of 5.1%, return on assets of 3.8% and asset turnover of 4.14x. Revenue per employee was €1.21M, indicating strong productivity.